Chimerism in C57BL/6 recipients of BALB/c BMCs
BM dose and anti-NIK1.1 mAb treatment . | Long-term donor chimerism, no./total (%) . | Donor chimerism in chimeric mice 24 wk after transplantation, % . | . | . | ||
|---|---|---|---|---|---|---|
| . | . | GR-1+ . | B220+ . | CD3+ . | ||
| 100 × 106 cells | ||||||
| Without treatment | 5/5 (100) | 26.7 ± 9.5 | 5.3 ± 2.5 | 1.4 ± 0.9 | ||
| With treatment | 5/5 (100) | 37.3 ± 11.1 | 7.1 ± 3.9 | 1.8 ± 1.1 | ||
| 30 × 106 cells | ||||||
| Without treatment | 1/5 (20)* | 6.2 | 1.4 | 0.1 | ||
| With treatment | 5/5 (100) | 5.8 ± 3.3 | 1.6 ± 0.9 | 0.3 ± 0.2 | ||
BM dose and anti-NIK1.1 mAb treatment . | Long-term donor chimerism, no./total (%) . | Donor chimerism in chimeric mice 24 wk after transplantation, % . | . | . | ||
|---|---|---|---|---|---|---|
| . | . | GR-1+ . | B220+ . | CD3+ . | ||
| 100 × 106 cells | ||||||
| Without treatment | 5/5 (100) | 26.7 ± 9.5 | 5.3 ± 2.5 | 1.4 ± 0.9 | ||
| With treatment | 5/5 (100) | 37.3 ± 11.1 | 7.1 ± 3.9 | 1.8 ± 1.1 | ||
| 30 × 106 cells | ||||||
| Without treatment | 1/5 (20)* | 6.2 | 1.4 | 0.1 | ||
| With treatment | 5/5 (100) | 5.8 ± 3.3 | 1.6 ± 0.9 | 0.3 ± 0.2 | ||
Two groups of C57BL/6 mice were treated with anti-CD40L mAb and 100 × 106 BALB/c BMCs at day 0. One group (n = 5) received 2 injections of anti-NK1.1 mAb at day 5 and day 1 before transplantation, and the other group (n = 5) did not have depletion of NK1.1+ cells. Two other groups of C57BL/6 mice were treated with anti-CD40L mAb and 30 × 106 BALB/c BMCs on day 0. Again, one group (n = 5) received 2 injections of anti-NK1.1 mAb at day 5 and day 1 before transplantation and the other group (n = 5) was not depleted for NK1.1+ cells.
Two mice in this group showed transient chimerism, but no detectable chimerism was observed 12 weeks after transplantation.